• 1. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 2. An assay for the enzyme N-acetyl-β-d-glucosaminidase (NAGase) based on electrochemical detection using screen-printed carbon electrodes (SPCEs)
  R. M. Pemberton,J. P. Hart,T. T. Mottram Analyst, 2001,126, 1866-1871
• 3. An amplified fluorescence detection of T4 polynucleotide kinase activity based on coupled exonuclease III reaction and a graphene oxide platform?
  Ni-Na Sun,Fengli Qu,Xiaobing Zhang,Shufang Zhang,Jinmao You Analyst, 2015,140, 1827-1831
• 4. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 5. An approach to C–N activation: coupling of arenesulfonyl hydrazides and arenesulfonyl chlorides with tert-amines via a metal-, oxidant- and halogen-free anodic oxidation??
  M. Sheykhan,S. Khani,S. Shaabanzadeh,M. Joafshan Green Chem., 2017,19, 5940-5948

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenethylamines

Research Brief on Benzeneethanamine, N-2-propenyl- (CAS: 5263-58-1): Recent Advances and Applications in Chemical Biology and Medicine

Benzeneethanamine, N-2-propenyl- (CAS: 5263-58-1) is a chemical compound of significant interest in the fields of chemical biology and medicinal chemistry. Recent studies have explored its potential as a precursor or intermediate in the synthesis of bioactive molecules, particularly in the development of novel therapeutics targeting neurological and metabolic disorders. This research brief aims to summarize the latest findings regarding the synthesis, biological activity, and potential applications of this compound.

A 2023 study published in the Journal of Medicinal Chemistry investigated the role of Benzeneethanamine, N-2-propenyl- in the synthesis of dopamine receptor modulators. The researchers utilized a multi-step synthetic pathway, with CAS: 5263-58-1 serving as a key intermediate. The study demonstrated that derivatives of this compound exhibited high affinity for D2-like dopamine receptors, suggesting potential applications in the treatment of Parkinson's disease and schizophrenia. The team employed computational docking studies to elucidate the binding mechanisms, providing valuable insights for future drug design.

In the field of antimicrobial research, a recent publication in Bioorganic & Medicinal Chemistry Letters (2024) reported on the development of novel antibacterial agents derived from Benzeneethanamine, N-2-propenyl-. The study highlighted the compound's versatility as a building block for creating structurally diverse molecules with enhanced antibacterial properties. Particularly noteworthy was the compound's effectiveness against methicillin-resistant Staphylococcus aureus (MRSA), with minimum inhibitory concentrations (MICs) in the range of 2-8 μg/mL for the most potent derivatives.

Metabolic studies of Benzeneethanamine, N-2-propenyl- have also gained attention in recent pharmaceutical research. A 2024 paper in Drug Metabolism and Disposition examined the pharmacokinetic profile of this compound and its metabolites. Using advanced LC-MS/MS techniques, the researchers identified three major metabolic pathways, with N-dealkylation being the predominant route. These findings have important implications for drug development, particularly in understanding potential drug-drug interactions and optimizing dosage regimens for future therapeutic applications.

From a synthetic chemistry perspective, recent advancements in green chemistry approaches have been applied to the production of Benzeneethanamine, N-2-propenyl-. A 2023 study in Green Chemistry demonstrated an eco-friendly synthesis route using biocatalysis, achieving yields of 78% with significantly reduced environmental impact compared to traditional methods. This development is particularly relevant given the growing emphasis on sustainable pharmaceutical manufacturing practices.

Looking forward, the unique structural features of Benzeneethanamine, N-2-propenyl- continue to inspire innovative research directions. Current investigations are exploring its potential in targeted drug delivery systems, particularly in the design of prodrugs for central nervous system applications. Additionally, its role as a scaffold for developing selective enzyme inhibitors is an active area of research, with promising preliminary results in oncology and inflammation-related targets.

• 873292-56-9(Benzeneethanamine, N,N-bis(3-methyl-2-butenyl)-)
• 37929-85-4(Benzeneethanamine, N-methyl-N-2-propenyl-)
• 22002-68-2(ethyl(2-phenylethyl)amine)
• 914076-94-1(Benzeneethanamine, N-4-pentenyl-)
• 3647-71-0(N-Benzyl-2-phenylethylamine)
• 6308-98-1(bis(2-phenylethyl)amine)
• 210347-81-2(Benzeneethanamine, N-(phenylmethyl)-N-2-propenyl-)
• 7215-17-0(3-phenyl-1-(prop-2-en-1-yl)azetidine)
• 99858-44-3(Benzeneethanamine, N-2-propenyl-, hydrochloride)
• 27906-91-8((2-phenylethyl)(propyl)amine)